Maze Therapeutics CMO Sells 15,000 Shares in Plan

Maze Therapeutics President, R&D & CMO Harold Bernstein reported an automatic stock transaction under a Rule 10b5-1 trading plan.

Rhea-AI Filing Summary

Maze Therapeutics President, R&D & CMO Harold Bernstein reported an automatic stock transaction under a Rule 10b5-1 trading plan. On February 2, 2026, he exercised a stock option for 15,000 shares of common stock at an exercise price of $10.42 per share.

On the same date, he sold a total of 15,000 common shares in several market transactions at weighted average prices of $44.205, $45.8891, $46.3732 and $47.23 per share, with actual sale prices ranging from $44.15 to $47.17 per share. After these sales, he reported 0 shares of common stock directly owned and 297,407 stock options remaining, linked to an award that began vesting on October 3, 2023.

Insider Trade Summary

Exercise and Sale: 15,000 shares ($534K approx. pre-tax spread)

Exercise and Sale 6 txns

Insider Bernstein Harold

Role President, R&D & CMO

Sold 15,000 shs ($690K)

Approx. gross sale proceeds $690K

Approx. exercise cost $156K

Approx. pre-tax spread $534K

Type	Security	Shares	Price	Value
Exercise	Stock Option (Right to Buy)	15,000	$0.00	$0.00
Exercise	Common Stock	15,000	$10.42	$156K
Sale	Common Stock	600	$44.205	$27K
Sale	Common Stock	8,364	$45.8891	$384K
Sale	Common Stock	5,936	$46.3732	$275K
Sale	Common Stock	100	$47.23	$5K

Holdings After Transaction: Stock Option (Right to Buy) — 297,407 contracts (Direct); Common Stock — 0 shares (Direct)

Footnotes (5)

1. F1. This transaction was effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on September 29, 2025.
2. F2. The reported price in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $44.15 to $44.29 per share, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in this footnote and in footnotes 3 and 4 of this Form 4.
3. F3. The reported price in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $45.20 to $46.19 per share, inclusive.
4. F4. The reported price in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $46.20 to $47.17 per share, inclusive.
5. F5. The option vested as to 1/4th of the total award on October 3, 2023, and thereafter vested or vests as to 1/48th of the total award on the monthly anniversary thereof, subject to the reporting person's continued service to the Issuer on each vesting date.

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

What insider transaction did MAZE executive Harold Bernstein report?

Harold Bernstein reported exercising 15,000 Maze Therapeutics (MAZE) stock options and selling 15,000 common shares on February 2, 2026. The exercise price was $10.42 per share, and sales occurred in multiple trades at weighted average prices between $44.205 and $47.23 per share.

At what prices did MAZE shares sell in Harold Bernstein’s Form 4 filing?

The Form 4 shows weighted average sale prices of $44.205, $45.8891, $46.3732 and $47.23 per MAZE share. Footnotes explain the actual trades occurred in ranges from $44.15 up to $47.17 per share across multiple individual transactions.

How many MAZE shares does Harold Bernstein own after this Form 4 transaction?

After the reported transactions, Harold Bernstein reported owning 0 shares of MAZE common stock directly. He continues to hold 297,407 stock options, tied to an award that began vesting on October 3, 2023, with ongoing monthly vesting subject to continued service.

Was the MAZE insider sale under a Rule 10b5-1 trading plan?

Yes. The Form 4 states the MAZE transactions were executed under a Rule 10b5-1 trading plan adopted by Harold Bernstein on September 29, 2025. Such plans pre-schedule trades, creating a structured framework for selling shares over time.

What stock option did Harold Bernstein exercise in the MAZE Form 4?

He exercised a stock option to buy 15,000 MAZE common shares at $10.42 per share. The option originally covered more shares, began vesting October 3, 2023, and vests 1/48th of the total award monthly, subject to his continued service with the company.

What role does Harold Bernstein hold at Maze Therapeutics (MAZE)?

Harold Bernstein is identified as an officer of Maze Therapeutics (MAZE), serving as President, R&D & Chief Medical Officer. He is not listed as a director or 10% owner, but is a key executive with ongoing equity-based compensation through stock options.

AI-generated analysis. How Rhea-AI works. Not financial advice.

Form 4 Insider Transactions: What Each Field Means →

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

Accepted by SEC EDGAR 02/04/2026 - 04:25 PM Learn about SEC filing dates

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

X

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

Bernstein Harold

(Last) (First) (Middle)

C/O MAZE THERAPEUTICS, INC.

171 OYSTER POINT BOULEVARD, SUITE 300

(Street)

SOUTH SAN FRANCISCO CA 94080

(City) (State) (Zip)

2. Issuer Name and Ticker or Trading Symbol
Maze Therapeutics, Inc. [ MAZE ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

	Director		10% Owner
X	Officer (give title below)		Other (specify below)
	President, R&D & CMO

3. Date of Earliest Transaction (Month/Day/Year)
02/02/2026

4. If Amendment, Date of Original Filed (Month/Day/Year)

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price
Common Stock	02/02/2026		M(1)		15,000	A	$10.42	15,000	D
Common Stock	02/02/2026		S(1)		600	D	$44.205(2)	14,400	D
Common Stock	02/02/2026		S(1)		8,364	D	$45.8891(3)	6,036	D
Common Stock	02/02/2026		S(1)		5,936	D	$46.3732(4)	100	D
Common Stock	02/02/2026		S(1)		100	D	$47.23	0	D

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares
Stock Option (Right to Buy)	$10.42	02/02/2026		M(1)			15,000	(5)	10/26/2032	Common Stock	15,000	$0	297,407	D

Explanation of Responses:

1. This transaction was effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on September 29, 2025.

2. The reported price in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $44.15 to $44.29 per share, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in this footnote and in footnotes 3 and 4 of this Form 4.

3. The reported price in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $45.20 to $46.19 per share, inclusive.

4. The reported price in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $46.20 to $47.17 per share, inclusive.

5. The option vested as to 1/4th of the total award on October 3, 2023, and thereafter vested or vests as to 1/48th of the total award on the monthly anniversary thereof, subject to the reporting person's continued service to the Issuer on each vesting date.

	/s/ Courtney Phillips, as attorney-in-fact	02/04/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.